Showing results (171-180 of 179) with videos related to
Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 179 results.
Cancer Immunology Research|September 30, 2024
A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal CancerBrandon M Huffman, Osama E Rahma, Kevin Tyan, et al.ESMO Open|November 30, 2024
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancerS-H Lee, J Menis, T M Kim, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 17, 2022
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancerA Passaro, N Leighl, F Blackhall, et al.JTO Clinical and Research Reports|October 14, 2024
Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%-89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or CemiplimabBiagio Ricciuti, Arielle Elkrief, Jessica Lin, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 25, 2019
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registryJ Mazieres, A Drilon, A Lusque, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 11, 2024
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung CancerBiagio Ricciuti, Giuseppe Lamberti, Sreekar R Puchala, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 25, 2023
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 studyA Passaro, J Wang, Y Wang, et al.Journal for Immunotherapy of Cancer|January 25, 2024
Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term respondersBrandon M Huffman, Harshabad Singh, Lestat R Ali, et al.ESMO Open|January 24, 2026
Global advances and future directions in lung cancer care: expert consensus and strategic prioritiesM-L Meyer, S Peters, P A Jänne, et al.Pageof 18